Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 7Gastrointestinal 2Other solid neoplasm 1

Conditions

Rectal Neoplasms 2Colonic Neoplasms 2

Interventions

Fluorouracil 286Oxaliplatin 274Gemcitabine 222Capecitabine 221Leucovorin 219Bevacizumab 200Irinotecan 170pembrolizumab 140Cisplatin 132Cetuximab 111Radiotherapy 109Sorafenib 75Nivolumab 75130-nm albumin-bound paclitaxel 64Paclitaxel 63Albumin-Bound Paclitaxel 63Docetaxel 61Erlotinib Hydrochloride 57Panitumumab 56Radiosurgery 47Folfox protocol 46regorafenib 45Sunitinib 40Radiation 39Magnetic Resonance Spectroscopy 38durvalumab 33Surgical Procedures, Operative 33Trastuzumab 32Ramucirumab 32Cyclophosphamide 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × 2C4 antibody × Gastrointestinal × Clear all
NCT03365882 2026-02-10

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

SWOG Cancer Research Network

Phase 2 Completed
240 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT00551421 2015-03-31

Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
17 enrolled 7 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡